Carlsmed Inc (CARL) Stock Forecast & Price Target

Carlsmed is an AI-enabled medical technology company that provides customized surgical planning and implants for spine fusion procedures, with a focus on personalized solutions. The company has a strong growth trajectory and has shown excellent financial performance, with a revenue growth of 58.2% year-over-year in FY26 and a projected CAGR of 43% through FY28. The recent launch of aprevo Cervical and the potential for higher utilization among existing surgeon customers could lead to further revenue growth, potentially exceeding market expectations. Additionally, the company's proprietary aprevo Technology Platform and expanding surgeon base offer long-term growth potential. However, risks such as a concentrated customer base and the potential for higher operating expenses should be monitored by investors.

Carlsmed is experiencing strong top-line growth, with a 58.2% year-over-year and 6.3% quarter-over-quarter increase in total revenue largely driven by its lumbar products. While the company's lead times for aprevo in 1Q26 were only six days, suggesting high demand, there is a risk that existing customers may not see the value in expanding to the company's cervical products, potentially limiting future revenue growth and hindering the company's ability to expand its multiple and achieve a higher valuation. Additionally, while Carlsmed has received an NTAP for its aprevo Cervical products, it remains to be seen if this will incentivize sufficient adoption among existing customers to drive significant incremental revenue in the near term.